Harrow Reports Wider Q1 Loss, Negative Operating Cash Flow Amid Revenue Decline
HROW sits 62% above its 52-week low of $21.12 on elevated volume (2.1× avg).
Summary
Harrow, Inc. reported a wider net loss and a shift to negative operating cash flow in Q1 2026, driven by declining compounding revenue and increased operating expenses, despite a recent debt raise.
Key Events · Earnings and Guidance · HROW
-
Revenue Decline
Total revenues decreased by 7.58% to $44.203 million, primarily due to a 32.6% drop in compounding revenue and a 64.6% decline in IHEEZO sales.
-
Wider Net Loss
Net loss widened by 55.2% to $(27.602) million, and loss from operations nearly doubled, driven by increased R&D and personnel costs.
-
Negative Operating Cash Flow
The company shifted from generating $19.668 million in operating cash flow in Q1 2025 to using $8.992 million in Q1 2026.
-
Gross Margin Compression
Gross margins decreased in both the Branded (from 70.6% to 64.3%) and Compounding (from 63.4% to 54.0%) segments.
Analysis · HROW · Life Sciences
Harrow, Inc. reported a significant operational downturn in Q1 2026, with total revenues declining and net loss widening substantially. The company experienced a notable shift to negative cash flow from operations, indicating increased cash burn from core business activities. While recent debt financing has bolstered the cash balance, the underlying operational performance and gross margin compression across segments present challenges. The updated risk factors highlight ongoing pressures from pricing and reimbursement, which could continue to impact profitability.
At the time of this filing, HROW was trading at $34.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $21.12 to $54.85. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.